IMAX Corporation Executives Adopt 10b5-1 Trading Plans
Under Mr. Gelfond's 10b5-1 trading plan, he will be able to sell up to 720,000 shares in equal monthly installments over a 12-month period. The plan includes escalating minimum prices relating to the sale of shares over the course of the plan. Under Mr. Wechsler's plan, he will be able to sell up to 900,000 shares, in equal monthly installments over a 10-month period. If all 1.62 million shares were to be sold throughout the duration of the plans, Mssrs. Gelfond and Wechsler would continue to own approximately 65% of their combined share ownership in the Company. In addition, Mssrs. Gelfond and Wechsler have put in place a plan to exercise approximately half of their stock appreciation rights at predetermined times and amounts over the duration of their 10b5-1 plans, which is designed to reduce the impact of these awards on the Company's financial results.
Transactions under both plans will be disclosed publicly through Form 144 and Form 4 filings with the
In a joint statement, Mssrs. Gelfond and Wechsler said, "We believe strongly in
About
IMAX(R), IMAX(R) 3D, IMAX DMR(R), Experience It In IMAX(R), An IMAX 3D Experience(R) and The IMAX Experience(R) are trademarks of
The
This press release contains forward looking statements that are based on management's assumptions and existing information and involve certain risks and uncertainties which could cause actual results to differ materially from future results expressed or implied by such forward looking statements. Important factors that could affect these statements include, but are not limited to, general economic, market or business conditions, including the length and severity of the current economic downturn, the opportunities that may be presented to and pursued by the Company, the performance of IMAX DMR films, conditions in the in-home and out-of home entertainment industries, the signing of theatre system agreements, changes and developments in the commercial exhibition industry, the failure to convert theatre system backlog into revenue, investments and operations in foreign jurisdictions, foreign currency fluctuations and the Company's prior restatements and the related litigation and ongoing inquiries by the SEC and the OSC. These factors and other risks and uncertainties are discussed in the Company's most recent Annual Report on Form 10-K and most recent Quarterly Reports on Form 10-Q.
CONTACT:
Media:
212-821-0155
[email protected]
Investors:
212-821-0121
[email protected]
Rogers & Cowan,
Elliot Fischoff
[email protected]
310-854-8128
Business Media:
Whit Clay
212-446-1864
[email protected]